CoreValve, S.A.'s 18-French Revalving(RM) System Demonstrated 'Live' At TCT 2006

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that its third-generation, proprietary aortic heart valve was implanted successfully — non-surgically — in a ‘high-risk’ patient using CoreValve’s percutaneous, 18-French ReValving™ System, at the 18th annual ‘Transcatheter Cardiovascular Therapeutics’ (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF). TCT is one of the largest interventional vascular medicine meetings in the world.